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The p16INK4a gene encodes a protein, p16, which is a D-type
cyclin-dependent kinase (cdk) inhibitor that blocks the ability of
cdk4 to interact with cyclin D1 and stimulate the progression of
eukaryotic cells through G1 phase of the cell cycle (Serrano et al,
1993). The p16INK4a gene was found to be inactivated in a large
percentage of tumour cell lines (Kamb et al, 1994; Nobori et al,
1994; Okamoto et al, 1994). However, its inactivation is observed
less frequently in primary tumours than in the cell lines (Serrano,
1997). There are three main mechanisms of genetic inactivation of
p16INK4a: deletions of both alleles, deletion of one allele and intra-
genic mutation of the remaining allele; and deletion of one allele
and methylation-mediated silencing of the remaining allele
(Serrano, 1997).
Gene silencing has been associated with methylation of a CpG
island located in, or near, promoters and 5¢ regulatory regions
(Herman et al, 1994; Issa et al, 1994). CpG islands are G+C rich
regions that show a higher frequency of CpG dinucleotides than is
normally seen in the vertebrate genome, that are not methylated in
the germline and, with some exceptions, are usually unmethylated
in normal somatic cells (Bird, 1986). In contrast, widespread
methylation of CpG islands occurs on autosomal genes during the
carcinogenic process (Jones and Buckley, 1990; Laird and
Jaenisch, 1994). The exon 1 coding sequences of the p16INK4a gene
reside within 5¢ CpG islands (Gonzalez-Zulueta et al, 1995), and
transcriptional block of p16INK4a by methylation of its 5¢ CpG
island has been reported in many cancer cell lines (Gonzalez-
Zulueta et al, 1995; Herman et al, 1995; Merlo et al, 1995; Poster
et al, 1998), as well as in primary tumours (Gonzalez-Zulueta et al,
1995; Herman et al, 1995; Merlo et al, 1995). Among them, breast
cancer displayed a rate of 31% of de novo methylation (Herman
et al, 1995).
For more than two decades scientists have known that minute
quantities of DNA are present in the plasma of normal individuals,
and that increased quantities circulate in patients with chronic
autoimmune disorders and cancer (Leon et al, 1977; Shapiro et al,
1983). The source of this circulating DNA remains enigmatic. A
certain amount seems to originate from lymphocytes (Anker et al,
1975), but in cancer patients, a tumour-related origin cannot be
ruled out (Stroun et al, 1987, 1989), as these individuals show
greater levels of DNA than healthy subjects. Moreover, these
levels correlate inversely with outcome and tend to fall with
effective treatment (Leon et al, 1977). More recent studies have
involved the use of polymerase chain reaction (PCR) to amplify
plasma DNA and identify genetic alterations in it that correspond
to the same alterations found in tumour DNA. The sensitivity of
PCR techniques in the detection of these alterations in plasma
DNA may be as high as 86% (Anker et al, 1997); and the speci-
ficity shown in the studies in this field ranged from about 28% to
100% (Anker et al, 1997; Mulcahy et al, 1998; Sanchez-Cespedes
et al, 1998). Among these alterations, K-ras, N-ras and p53 gene
mutations have been reported in the plasma DNA of patients
with pancreatic cancer, colorectal cancer and acute myelogenous
leukaemia (Vasioukhin et al, 1994; Anker et al, 1997; Hibi et al,
1998). Likewise, specific microsatellite alterations have been
detected in patients with small-cell lung cancer (SCLC) (Chen et
al, 1996), non-SCLC (Sanchez-Cespedes et al, 1998), head and
neck carcinomas (Nawroz et al, 1996) and clear cell renal carci-
noma (Goessl et al, 1998).
In this context, we investigated whether one of the inactivation
mechanisms of p16INK4a, hypermethylation, was present in our
patients with breast carcinomas and the possibility of finding this
phenomenon in plasma DNA of these patients.
MATERIALS AND METHODS
Tissue samples and DNA extraction
All participants were informed of the nature of the study, and gave
their informed consent. A tumour sample was obtained at surgery
from each of 35 patients with breast cancer, immediately after
resection, and snap-frozen in liquid nitrogen until processing. All
specimens underwent histological examination to confirm the
Aberrant DNA methylation of the p16INK4a gene in plasma
DNA of breast cancer patients
JM Silva, G Dominguez, MJ Villanueva, R Gonzalez, JM Garcia, C Corbacho, M Provencio, P España and F Bonilla
Department of Medical Oncology, Clinica Puerta de Hierro, 28035-Madrid, Spain
Summary Hypermethylation of exon 1 of p16INK4a was examined in tumour and plasma DNA of a series of breast cancer patients. De novo
methylation was observed in the tumours of eight patients (23%), and in plasma DNA in five (14%) of these eight patients. Our data show that
de novo methylation of exon 1 of p16INK4a can be demonstrated in plasma DNA of breast cancer patients, a fact that provides additional
evidence of the tumour-related origin of free plasma DNA in cancer patients.
Keywords: p16INK4a gene; DNA methylation; breast cancer; plasma DNA; CpG islands
1262
British Journal of Cancer (1999) 80(8), 1262–1264
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0495
Received 10 September 1998
Revised 21 December 1998
Accepted 12 January 1999
Correspondence to: F Bonilla, Molecular Genetics Unit, Clinica del Trabajo,
Avd. de la Reina Victoria 21, 28003-Madrid, SpainPlasma DNA methylation in breast cancer patients 1263
British Journal of Cancer (1999) 80(8), 1262–1264 © 1999 Cancer Research Campaign 
diagnosis of invasive breast carcinoma. Pathological diagnosis and
clinical evaluation disclosed no evidence of metastatic dissemina-
tion in any patient. A blood sample was collected from each
patient before surgery. DNA extraction of tumour samples and
of peripheral mononuclear cells (used as normal DNA to avoid
possible molecular alterations of normal breast tissue) was
performed by a non-organic method (Oncor Inc, Gaithersburg,
MD, USA). Plasma DNA was purified on Qiagen columns (Qiamp
Blood Kit; Qiagen Inc., Hilden, Germany) according to the blood
and body fluids protocol, introducing the following modifications.
Between 7.5 and 12 ml of plasma were heated at 99°C for 5 min
on a heat block. The heated sample was then centrifuged at
14 000 rpm for 30 min, after which the clear supernatant was
collected (Lo et al, 1997). Proteinase K (20 mg ml–1) (Boehringer
Mannheim, Mannheim, Germany) and buffer AL (Qiagen Inc.)
were added in a 1/10 proportion with respect to the collected
supernatant and incubated overnight at 55°C.
PCR-based methylation assay
A PCR assay, based on the inability of some restriction enzymes to
cut methylated sequences as described (Singer-Sam et al, 1990),
was used to analyse the methylation status of the first exon of
p16INK4a, and the PstI and SacII sites were examined. Analysis of
DNA digests was performed according to the manufacturer’s
directions (Promega, Madison, WI, USA). DNA (250 ng) was
digested overnight with 2.5 units of enzyme; 100 ng of the
digested DNA were amplified with primers flanking the restriction
sites. Amplification of b-globin, adding the corresponding
primers, was used as internal control of the reaction in a multiplex
PCR. (There are no restriction sites in the b-globin sequence
selected for PstI and SacII). The primer set used for methylation
analysis of exon 1 of p16INK4a was 5¢-GGG AGC AGC ATG GAG
CCG-3¢ (sense) and 5¢-AGT CGC CCG CCA TCC CCT-3¢ (anti-
sense); and for b-globin, 5¢-CAA CTT CAT CCA CGT TCA CC-
3¢ (sense) and 5¢-GAA GAG CCA AGG ACA GGT AC-3¢
(antisense). The conditions were as follows: buffer 10X 2.5 ml,
dNTPs 200 mM, Cl2Mg 2.5 mM, exon 1 primers 0.6 mM, b-globin
primers 0.6 mM and 100 ng of the digested DNA as template and
dH2O to reach a total volume of 25 ml. This reaction mixture was
amplified with Ampli Taq Gold (Perkin Elmer, Roche Molecular
Systems Inc., Branchburg, NJ, USA): 94°C for 12 min, 35 cycles
of 94°C for 30 s, 61°C for 30 s and 72°C for 30 s, followed by
incubation at 72°C for 11 min. PCR products were resolved in 6%
acrylamide and stained with a non-isotopic silver nitrate method
(Oto et al, 1993). PCR-based methylation analysis using restric-
tion enzymes may be subject to variability if the DNA digestions
are not complete. To rule out the possibility of incomplete restric-
tion, all samples were digested overnight, and twice in indepen-
dent experiments. PCR amplifications from each of the duplicate
digests were repeated twice to ensure reproducibility of the results.
RESULTS
The methylation status of two CpG sites (PstI and SacII) within
the first exon of p16INK4a was examined in tumour and normal
DNA of 35 patients with breast cancer. The sites were analysed by
a PCR-based assay using methylation-sensitive enzymes for DNA
cleavage, followed by PCR amplification of the digested DNA,
utilizing the aforementioned primers of the first exon of p16INK4a.
The analysis of normal DNA displayed no methylation of the exon
studied because no PCR product was generated following diges-
tion with the restriction enzyme used. After cutting with the
endonucleases, eight tumours (23%) showed de novo methylation
of exon 1 of p16INK4a, since PCR products were generated after
digestion. In all of these cases, methylation was observed after
digestion with PstI and SacII restriction enzymes. In the three
cases in which the second amplification of each of the duplicate
digested samples displayed discordant results, a third, decisive
amplification was performed. Plasma DNA extraction disclosed
concentrations ranging from 20 ng ml–1 to 178 ng ml–1, with an
average of 110 ng ml–1 among our 35 patients, none of whom
presented metastases. Seventeen healthy controls were also
analysed. Their plasma DNA concentrations were lower than
those of cancer patients, ranging between 0 and 45 ng ml–1. In all
cases, the DNA extracted was suitable for molecular study; in
order to test it, exon 1 of p16INK4a was amplified prior to the PCR-
based methylation assay, and the products electrophoresed in 1.5%
agarose were similar to the products obtained with control DNA.
Next, plasma DNA was analysed for presence of methylation,
using the same PCR-based methylation assay performed in tumour
DNA. In five (14%) of the eight patients that showed de novo
methylation in tumour DNA, this phenomenon was demonstrated
in plasma DNA (Figure 1). Plasma DNA methylation was not
observed in any of the 27 cases in which there was no methylation
in tumour DNA.
DISCUSSION
Exon 1 of p16INK4a is contained in a CpG island that has a density
of CpG of 8.6%, which exceeds the theoretically expected
frequency of CpG dinucleotides (Bird, 1986; Gardiner-Garden and
Frommer, 1987; Merlo et al, 1995) in mammalian DNA. These
islands are unmethylated in normal tissue (Merlo et al, 1995)
although, exceptionally, the absence of p16INK4a expression in asso-
ciation with methylation of its 5¢ CpG could be observed in normal
colon mucosa (Gonzalez-Zulueta et al, 1995). The present rate,
23%, of de novo methylation found in primary tumours of our
patients with breast cancer is lower than the 31% reported by
Herman et al (1995). The number of tumours checked and restric-
tion enzymes used may influence this result.
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Figure 1 Photograph of the gels showing the PCR-based methylation
analysis of exon 1 of the p16INK4a gene in samples of tumour (T) and plasma
(P) DNA. (A) Results after DNA digestion with SaeII restriction enzyme,
(B) results for the same cases after digestion with PstI restriction enzyme. The
different lanes are as follows: lane 1, b-globin alone in a control case; lane 2,
exon 1 of p16INK4a isolated in a control; lanes T1 and P1 (patient no. 1),
amplification of exon 1 of p16INK4a after digestion with restriction enzyme SaeII
in tumour DNA (T1) and plasma DNA (P1), indicating presence of methylation;
lanes T2, T3 and P2, P3, corresponding to patient no. 2 and 3, no amplification
of exon 1 of p16INK4a was present after digestion, suggesting absence of DNA
methylation1264 JM Silva et al
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In studies reporting the same type of molecular changes in both
tumour DNA and plasma DNA (Vasioukhin et al, 1994; Chen et al,
1996; Nawroz et al, 1996; Anker et al, 1997; Hibi et al, 1998;
Sanchez-Cespedes et al, 1998), molecular markers have been
selected that display a high rate of specific alterations. However, to
our knowledge, exon 1 of p16INK4a had not been utilized to date
to check plasma DNA in breast cancer patients, and there are no
available data concerning its informativeness. We found 14% of
de novo methylation in plasma DNA of our patients, a fact that
demonstrates that the existence of plasma DNA in patients
harbouring a breast carcinoma is a tangible observation. The
finding that the aberrant DNA methylation in exon 1 of p16INK4a in
plasma DNA of these patients is identical to the alteration present
in the corresponding carcinomas indicates that hypermethylated
plasma DNA derives from the primary tumour. However, the
origin of plasma DNA remains speculative; thus, lymphocytes and
other molecular mononuclear blood cells may be a direct source of
plasma DNA, as may cells of solid tissues with a high turnover rate
such as tumour cells (Stroun et al, 1989). In this context, the
exhibition of the molecular change in tumour DNA but not in
plasma DNA, as occurred in three of our patients, may be the
result of the blocking of the incorporation of free tumour DNA
from tumour cells into the blood, or a possible increase in the rate
of the plasma DNA degradation process mediated by nucleases.
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